Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Adjuvant therapy for breast cancer often involves sequential radiotherapy and endocrine therapy.
• Emerging evidence suggests combining radiotherapy with endocrine therapy may enhance treatment efficacy.
• Understanding estrogen's role in irradiated breast cancer cells is crucial for optimizing treatment protocols.

Purpose of the Study:

• To investigate the effects of 17-beta-estradiol (E(2)) on breast cancer cells following gamma-ray irradiation.
• To elucidate the molecular mechanisms by which estrogen influences the behavior of irradiated breast cancer cells (IR-cells).

Main Methods:

• Functional genomic analysis was employed to study MCF-7 breast cancer cells.
• The impact of 17-beta-estradiol (E(2)) on irradiated cells was assessed.
• Key cellular pathways, including p53/p21(waf1/cip1)/Rb, were investigated.

Main Results:

• Estrogen (E(2)) was found to sustain the growth of irradiated breast cancer cells.
• E(2) prevented radiation-induced cell cycle arrest and did not alter apoptosis rates.
• Estrogen influenced the p53/p21(waf1/cip1)/Rb pathway, decreasing p21(waf1/cip1) binding to cyclin E and promoting Rb hyperphosphorylation, which may allow cell cycle progression.

Conclusions:

• Estrogen plays a role in maintaining breast cancer cell growth post-irradiation by affecting cell cycle regulation.
• These findings provide insights into the molecular basis of estrogen's effect on irradiated cells.
• The results support a rational basis for the sequential administration of radiation and endocrine therapies in breast cancer treatment.